Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of MM
Must have MM that is relapsed or refractory
Has received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
Measurable disease, as defined by at least one of the following: (1) serum M protein 0.5 g/dL or higher, (2) urine M protein 200 mg/24 hour or higher, and (3) serum immunoglobulin free light chain (FLC) 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda FLC ratio.
Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1
Life expectancy of greater than 3 months in the opinion of the investigator
Adequate hematologic, renal, and hepatic function
You may not be if
Parts A and D: Prior treatment with a BCMA-directed therapy
History of another malignancy within 3 years
Active cerebral or meningeal disease related to the underlying malignancy
Uncontrolled Grade 3 or higher infection
Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR-T-cell therapy must be completed 8 weeks before first dose of study drug.
Combination therapy only:
1. Known intolerance to corticosteroids
2. Uncontrolled psychoses
Clareo Health | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
